8-K: Humacyte Terminates $80M At-The-Market Equity Offering

Humacyte, Inc. has terminated its Open Market Sale Agreement with Jefferies LLC, ending its ability to sell up to $80 million in common stock.

Summary

• Humacyte, Inc. delivered a notice to Jefferies LLC on November 21, 2025, to terminate their Open Market Sale Agreement.
• The Agreement, originally entered into on September 1, 2022, allowed Humacyte to offer and sell common stock with an aggregate offering price of up to $80,000,000 through Jefferies as an agent.
• The termination will become effective 10 days after the notice was delivered.
• Humacyte is not subject to any termination penalties related to the termination of this Agreement.

Sentiment

Score: 5

Explanation: The termination of the ATM agreement is a procedural event. While it removes a capital raising option, the lack of penalties is positive. The overall impact depends on the company's current capital needs and alternative financing strategies, which are not detailed in this filing.

Positives

• The company is not subject to any termination penalties related to the termination of the Open Market Sale Agreement.

Negatives

• The termination removes a flexible mechanism for Humacyte to raise up to $80,000,000 in equity capital.

Risks

• Future capital needs may require Humacyte to seek alternative financing methods, which could be less favorable or more complex than the terminated ATM facility.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the procedural termination of the agreement.

Management Comments

• Dale A. Sander, Chief Financial Officer, Chief Corporate Development Officer and Treasurer, signed the report on behalf of Humacyte, Inc.

Industry Context

The termination of an At-The-Market (ATM) equity facility is a company-specific capital markets event. While ATM facilities are common financing tools for growth-stage companies, particularly in the biotech sector, this termination does not directly reflect broader industry trends but rather Humacyte's specific capital strategy.

Stakeholder Impact

• Shareholders may view the termination as removing a potential source of future equity dilution, but it also eliminates a flexible capital raising tool for the company.

Next Steps

• The termination of the Open Market Sale Agreement will become effective 10 days after November 21, 2025.

Key Dates

Recommendation

The termination of the $80 million ATM facility removes a flexible equity financing option for Humacyte. While there are no termination penalties, investors should monitor the company's future capital requirements and alternative funding strategies. This event alone does not significantly alter the fundamental investment thesis but warrants a 'hold' as investors await further clarity on the company's financial plans.

Keywords

Humacyte, HUMA, Jefferies, ATM offering, equity offering, capital raise, termination, common stock, SEC filing, 8-K